AR067584A1 - Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos - Google Patents
Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicosInfo
- Publication number
- AR067584A1 AR067584A1 ARP080103081A ARP080103081A AR067584A1 AR 067584 A1 AR067584 A1 AR 067584A1 AR P080103081 A ARP080103081 A AR P080103081A AR P080103081 A ARP080103081 A AR P080103081A AR 067584 A1 AR067584 A1 AR 067584A1
- Authority
- AR
- Argentina
- Prior art keywords
- conjugate
- antibody against
- antifusogenic peptides
- peptides
- antibody
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
La presente solicitud se refiere a un conjugado que consta de dos o más péptidos antifusogénicos y un anticuerpo anti-CD4 (mAb CD4) caracterizado porque de uno a ocho péptido antifusogénicos están conjugados en cada caso con un extremo de las cadenas largas y/o cortas de dicho anticuerpo anti-CD4 y al uso farmacéutico de dicho conjugado.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07014335 | 2007-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR067584A1 true AR067584A1 (es) | 2009-10-14 |
Family
ID=38825000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103081A AR067584A1 (es) | 2007-07-20 | 2008-07-17 | Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090022720A1 (es) |
EP (2) | EP2178566A1 (es) |
JP (1) | JP2010534212A (es) |
KR (1) | KR20100049547A (es) |
CN (2) | CN103554271A (es) |
AR (1) | AR067584A1 (es) |
AU (1) | AU2008280443B2 (es) |
BR (1) | BRPI0814533A2 (es) |
CA (1) | CA2693663A1 (es) |
CL (1) | CL2008002092A1 (es) |
IL (1) | IL202565A0 (es) |
PE (1) | PE20090503A1 (es) |
TW (1) | TW200914467A (es) |
WO (1) | WO2009012944A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010003622A (es) | 2007-10-12 | 2010-04-14 | Hoffmann La Roche | Expresion proteinica a partir de acidos nucleicos multiples. |
JPWO2010087131A1 (ja) * | 2009-01-28 | 2012-08-02 | 学校法人東海大学 | Hiv複製抑制剤、及びその利用 |
ES2535704T3 (es) | 2010-09-14 | 2015-05-14 | F. Hoffmann-La Roche Ag | Polipéptido de fusión serpina-dedo |
CA2820134A1 (en) * | 2010-12-06 | 2012-06-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
US8440797B2 (en) | 2010-12-06 | 2013-05-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (ar) * | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
KR20170138558A (ko) | 2015-04-24 | 2017-12-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | Hiv 융합을 표적으로 하는 폴리펩티드 |
CN105039379A (zh) * | 2015-08-31 | 2015-11-11 | 浙江大学 | 一种大肠杆菌无细胞体系生产HIV-1 gp41重组抗原的方法 |
EP3559042A4 (en) * | 2016-12-22 | 2020-11-25 | Icahn School of Medicine at Mount Sinai | ANTI-LILRB3 ANTIBODIES AND METHOD OF USING THEREOF |
KR20200040819A (ko) * | 2017-08-16 | 2020-04-20 | 브리스톨-마이어스 스큅 컴퍼니 | 항체를 표적화하기 위한 항 ctla-4 프로바디 치료제 |
WO2020053239A1 (en) * | 2018-09-11 | 2020-03-19 | Nanotag Biotechnologies Gmbh | Epitope tags recognized by specific binders |
WO2020168024A1 (en) * | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
CN113461811A (zh) * | 2021-06-30 | 2021-10-01 | 复旦大学 | 一种双特异性抗hiv-1抗体 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8603765D0 (en) * | 1986-02-15 | 1986-03-19 | Beecham Wuelfung Gmbh & Co Kg | Compounds |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5202238A (en) * | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) * | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
JPH0468776A (ja) * | 1990-07-04 | 1992-03-04 | Pioneer Electron Corp | 情報記録及び静止画再生装置 |
WO1992009305A1 (en) | 1990-11-27 | 1992-06-11 | Biogen, Inc. | Anti cd-4 antibodies blocking hiv-induced syncytia |
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
DE69233011T2 (de) | 1991-07-25 | 2003-11-06 | Idec Pharma Corp | Rekombinante antikörper zur humanen therapie |
WO1994026910A1 (en) | 1993-05-12 | 1994-11-24 | Xoma Corporation | Immunotoxins comprising gelonin and an antibody |
FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
CA2140663C (en) * | 1992-07-20 | 2004-01-27 | Carl T. Wild | Compounds which inhibit hiv replication |
US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
US6017536A (en) * | 1993-06-07 | 2000-01-25 | Trimeris, Inc. | Simian immunodeficiency virus peptides with antifusogenic and antiviral activities |
US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
EP1161955A3 (en) | 1995-05-18 | 2001-12-19 | Ortho Pharmaceutical Corporation | Induction of immunological tolerance for graft transplantation by the use of humanized non-depleting anti-cd4 antibodies in combination with specific donor bone marrow cells |
EP0831873A4 (en) | 1995-06-07 | 2002-07-17 | Trimeris Inc | COMBINATORY THERAPY FOR THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS |
US5646480A (en) * | 1995-06-19 | 1997-07-08 | Northrop Grumman Corporation | Metal assist structure for an electroluminescent display |
DK0910659T3 (da) | 1996-06-03 | 2006-11-27 | United Biomedical Inc | Antistoffer mod et kompleks af CD4 og et kemokin-receptordomæne og anvendelse deraf mod HIV-infektioner |
US6020159A (en) | 1996-09-24 | 2000-02-01 | Smithkline Beecham Corporation | 3-dehydroquinate synthase |
WO1998033523A1 (en) | 1997-01-31 | 1998-08-06 | Biovation Limited | Vaccination methods and molecules |
EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
US20030103984A1 (en) * | 1998-05-04 | 2003-06-05 | Heinz Kohler | Fusion proteins of biologically active peptides and antibodies |
US6656906B1 (en) * | 1998-05-20 | 2003-12-02 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6258782B1 (en) * | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
EP1123309A2 (en) * | 1998-10-13 | 2001-08-16 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic tetrapeptides and their use as histone deacetylase inhibitor |
ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
US6138310A (en) * | 1999-04-23 | 2000-10-31 | Porper; Robert P. | Electric toothbrush having opposed bristle heads |
TWI230178B (en) * | 1999-05-13 | 2005-04-01 | Sumitomo Chemical Co | Liquid crystal polyester resin composition and molded article thereof |
US7582301B1 (en) | 1999-05-17 | 2009-09-01 | Conjuchem Biotechnologies, Inc. | Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides |
JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
US6430559B1 (en) * | 1999-11-02 | 2002-08-06 | Claritech Corporation | Method and apparatus for profile score threshold setting and updating |
AU2265701A (en) * | 1999-12-16 | 2001-06-25 | Tanox, Inc. | Anti-hiv-1 conjugates for treatment of hiv disease |
DK1252192T3 (da) * | 2000-02-11 | 2006-11-20 | Merck Patent Gmbh | Forbedring af antistofbaserede fusionsproteiners serumhalveringstid |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
BR0112111A (pt) * | 2000-06-29 | 2003-05-06 | Merck Patent Gmbh | Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina |
US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
CA2485064A1 (en) * | 2002-02-07 | 2003-08-14 | Delta Biotechnology Limited | Albumin-fused kunitz domain peptides |
US20040076637A1 (en) | 2002-09-27 | 2004-04-22 | Delmedico Mary Kay | HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus |
CA2498483A1 (en) * | 2002-09-27 | 2004-04-08 | Tanox, Inc. | Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
KR20050120663A (ko) | 2003-03-24 | 2005-12-22 | 세쿠오이아 파마큐티컬스 인코오퍼레이티드 | 장기간 작용하는 생물학적 활동 컨쥬게이트들 |
US7610156B2 (en) * | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US20050281829A1 (en) | 2003-05-06 | 2005-12-22 | Hehir Cristina A T | Fc chimeric proteins with anti-HIV drugs |
WO2004103312A2 (en) * | 2003-05-19 | 2004-12-02 | Progenics Pharmaceuticals, Inc. | Peptides useful as hiv fusion inhibitors |
WO2005021710A2 (en) * | 2003-06-02 | 2005-03-10 | University Of Miami | Chimeric molecules and methods of use |
BRPI0418304A (pt) | 2004-01-07 | 2007-05-02 | Trimeris Inc | peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv |
KR20080071134A (ko) * | 2005-10-24 | 2008-08-01 | 센토코 인코포레이티드 | Glp-2 모방체,폴리펩티드,조성물,방법 및 용도 |
TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
WO2008019817A1 (en) * | 2006-08-17 | 2008-02-21 | F. Hoffmann-La Roche Ag | A conjugate of an antibody against ccr5 and an antifusogenic peptide |
-
2008
- 2008-07-17 AR ARP080103081A patent/AR067584A1/es unknown
- 2008-07-17 US US12/218,693 patent/US20090022720A1/en not_active Abandoned
- 2008-07-17 CL CL2008002092A patent/CL2008002092A1/es unknown
- 2008-07-18 EP EP08784874A patent/EP2178566A1/en not_active Withdrawn
- 2008-07-18 AU AU2008280443A patent/AU2008280443B2/en not_active Ceased
- 2008-07-18 WO PCT/EP2008/005894 patent/WO2009012944A1/en active Application Filing
- 2008-07-18 EP EP12181231A patent/EP2526972A1/en not_active Withdrawn
- 2008-07-18 CA CA2693663A patent/CA2693663A1/en not_active Abandoned
- 2008-07-18 KR KR1020107001222A patent/KR20100049547A/ko not_active Application Discontinuation
- 2008-07-18 CN CN201310547459.9A patent/CN103554271A/zh active Pending
- 2008-07-18 JP JP2010517307A patent/JP2010534212A/ja active Pending
- 2008-07-18 TW TW097127550A patent/TW200914467A/zh unknown
- 2008-07-18 BR BRPI0814533-4A2A patent/BRPI0814533A2/pt not_active IP Right Cessation
- 2008-07-18 PE PE2008001231A patent/PE20090503A1/es not_active Application Discontinuation
- 2008-07-18 CN CN2008800253614A patent/CN102099057B/zh not_active Expired - Fee Related
-
2009
- 2009-12-07 IL IL202565A patent/IL202565A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2693663A1 (en) | 2009-01-29 |
KR20100049547A (ko) | 2010-05-12 |
EP2526972A1 (en) | 2012-11-28 |
BRPI0814533A2 (pt) | 2015-01-27 |
IL202565A0 (en) | 2010-06-30 |
EP2178566A1 (en) | 2010-04-28 |
PE20090503A1 (es) | 2009-04-29 |
WO2009012944A1 (en) | 2009-01-29 |
JP2010534212A (ja) | 2010-11-04 |
CN102099057A (zh) | 2011-06-15 |
AU2008280443A1 (en) | 2009-01-29 |
CN102099057B (zh) | 2013-11-13 |
TW200914467A (en) | 2009-04-01 |
CL2008002092A1 (es) | 2009-05-29 |
AU2008280443B2 (en) | 2013-08-01 |
CN103554271A (zh) | 2014-02-05 |
US20090022720A1 (en) | 2009-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR067584A1 (es) | Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos | |
CR20110091A (es) | Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos | |
NZ754810A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
NO20091064L (no) | Antistoffer mot IL-17A | |
BRPI0818780A2 (pt) | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos | |
CR20140398A (es) | Anticuerpos e inmunoconjugados anti-cd22 | |
CY1116261T1 (el) | Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων | |
NO20084356L (no) | Anti TAT226-antistoffer og immunokonjugater | |
NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
PH12016501995A1 (en) | Tubulysin derivatives | |
BR112015027322A8 (pt) | Compostos antissenso conjugados e sua utilização | |
CL2013000843A1 (es) | Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso. | |
MX2019006362A (es) | Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer. | |
BRPI0915552A2 (pt) | derivados de ciclosporina, seu uso e sua composição farmacêutica | |
ECSP12012307A (es) | Proteínas de unión a il-1 | |
CO6410314A2 (es) | Proteínas de unión a il-17 | |
CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
CL2011000117A1 (es) | Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende. | |
NO20083891L (no) | Anti-5T4 antistoffer og anvendelser derav | |
BRPI1005322A2 (pt) | anticorpo, composição farmacêutica e uso de pelo menos um anticorpo | |
BRPI0818288A2 (pt) | Proteínas conjugadas e peptídeos. | |
BRPI1010621A2 (pt) | derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso | |
BRPI0814963A2 (pt) | Pró-fármacos de dipeptóides e seu uso | |
IN2015DN02349A (es) | ||
IN2012DN04908A (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |